J Schlom

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Exercise enhances vaccine-induced antigen-specific T cell responses
    Connie J Rogers
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Vaccine 26:5407-15. 2008
  2. ncbi request reprint Therapeutic cancer vaccines
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA Electronic address
    Adv Cancer Res 121:67-124. 2014
  3. pmc Vaccines against human carcinomas: strategies to improve antitumor immune responses
    Claudia Palena
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Biomed Biotechnol 2010:380697. 2010
  4. pmc The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring
    Matteo Vergati
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Biomed Biotechnol 2011:182413. 2011
  5. ncbi request reprint Effects of conventional therapeutic interventions on the number and function of regulatory T cells
    Mario Roselli
    Medical Oncology Department of Internal Medicine Tor Vergata University Clinical Center University of Rome Tor Vergata Rome, Italy
    Oncoimmunology 2:e27025. 2013
  6. ncbi request reprint Recombinant cancer vaccines and new vaccine targets. Interview by Jenaid Rees
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Expert Rev Vaccines 12:1121-4. 2013
  7. pmc A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies
    Adrian Bot
    Kite Pharma Inc, Los Angeles, CA, USA
    J Transl Med 10:218. 2012
  8. pmc Therapeutic cancer vaccines: current status and moving forward
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm 8B09, Bethesda, MD 20892, USA
    J Natl Cancer Inst 104:599-613. 2012
  9. ncbi request reprint A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines
    J Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Artif Cells Blood Substit Immobil Biotechnol 31:193-228. 2003
  10. ncbi request reprint Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation
    J Schlom
    Laboratory of Tumour Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Dev Biol (Basel) 116:27-47. 2004

Detail Information

Publications105 found, 100 shown here

  1. pmc Exercise enhances vaccine-induced antigen-specific T cell responses
    Connie J Rogers
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Vaccine 26:5407-15. 2008
    ..These results suggest that coupling moderate exercise with vaccination may enhance vaccine efficacy for the prevention and/or therapy of numerous diseases...
  2. ncbi request reprint Therapeutic cancer vaccines
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA Electronic address
    Adv Cancer Res 121:67-124. 2014
    ..The importance of the tumor microenvironment, the appropriate patient population, and clinical trial endpoints is also discussed in the context of optimizing patient benefit from vaccine-mediated therapy. ..
  3. pmc Vaccines against human carcinomas: strategies to improve antitumor immune responses
    Claudia Palena
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Biomed Biotechnol 2010:380697. 2010
    ....
  4. pmc The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring
    Matteo Vergati
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Biomed Biotechnol 2011:182413. 2011
    ..This paper focuses on the role of T-regulatory cells, myeloid-derived suppressor cells, and tumor-associated macrophages in cancer and cancer immunotherapy and their role in immune monitoring...
  5. ncbi request reprint Effects of conventional therapeutic interventions on the number and function of regulatory T cells
    Mario Roselli
    Medical Oncology Department of Internal Medicine Tor Vergata University Clinical Center University of Rome Tor Vergata Rome, Italy
    Oncoimmunology 2:e27025. 2013
    ..These studies provide the rationale for the selective use of active immunotherapy regimens in combination with specific standard-of-care therapies to achieve the most beneficial clinical outcome among carcinoma patients...
  6. ncbi request reprint Recombinant cancer vaccines and new vaccine targets. Interview by Jenaid Rees
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Expert Rev Vaccines 12:1121-4. 2013
    ..He has recently been working on the design and characterization of recombinant vaccines for cancer therapy. ..
  7. pmc A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies
    Adrian Bot
    Kite Pharma Inc, Los Angeles, CA, USA
    J Transl Med 10:218. 2012
    ..This Editorial provides highlights of the first event held earlier this year and outlines the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy...
  8. pmc Therapeutic cancer vaccines: current status and moving forward
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm 8B09, Bethesda, MD 20892, USA
    J Natl Cancer Inst 104:599-613. 2012
    ..The potential influence of the appropriate patient population and clinical trial endpoint in vaccine therapy studies is discussed, as well as the potential importance of biomarkers in future directions of this field...
  9. ncbi request reprint A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines
    J Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Artif Cells Blood Substit Immobil Biotechnol 31:193-228. 2003
    ..In vivo, peptide-pulsed DCs infected with TRICOM vectors induced cytotoxic T lymphocyte activity markedly and significantly greater than peptide-pulsed DCs...
  10. ncbi request reprint Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation
    J Schlom
    Laboratory of Tumour Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Dev Biol (Basel) 116:27-47. 2004
  11. doi request reprint Paradigm shifts in cancer vaccine therapy
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, CCR, NCI, 10 Center Drive, Room 8B09, Bethesda, MD 20892, USA
    Exp Biol Med (Maywood) 233:522-34. 2008
    ..The unique features of this modality require the consideration of paradigm shifts both in the way cancer vaccine clinical trials are designed and in the way patient benefit is evaluated...
  12. pmc Cancer vaccines: moving beyond current paradigms
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:3776-82. 2007
    ..Consequently, evidence is emerging from several studies in which patient cohorts who first receive a cancer vaccine (as contrasted with control cohorts) benefit clinically from subsequent therapies...
  13. ncbi request reprint The diversity of T-cell co-stimulation in the induction of antitumor immunity
    J Schlom
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda MD 20892 1750, USA
    Immunol Rev 170:73-84. 1999
    ....
  14. ncbi request reprint Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules
    J W Hodge
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Building 10, Room 8B07, 10 Center Drive, Bethesda, MD 20892-1750, USA
    Vaccine 19:3552-67. 2001
    ....
  15. ncbi request reprint Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant
    E Kass
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 61:206-14. 2001
    ....
  16. ncbi request reprint The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells
    K Y Tsang
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 61:7568-76. 2001
    ....
  17. ncbi request reprint Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors
    A N Rad
    Howard Hughes Medical Institute, Research Scholar's Program at the National Institutes of Health, Bethesda, MD 20892, USA
    Crit Rev Oncol Hematol 39:43-57. 2001
    ..APCs infected with TRICOM vectors are shown to significantly enhance the activation of both naive and effector CD4(+) and CD8(+) T-cell populations. The use of TRICOM vectors in vaccine strategies is discussed...
  18. ncbi request reprint Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells
    M Zhu
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892-1750, USA
    Cancer Res 61:3725-34. 2001
    ..The use of this approach for in vitro studies and clinical applications in immunotherapy is discussed...
  19. ncbi request reprint Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects
    D W Grosenbach
    Laboratory of Tumor Immunology and Biology, National Cancer Institute/NIH, Bethesda, MD 20892-1750, USA
    Cancer Res 61:4497-505. 2001
    ....
  20. ncbi request reprint Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3)
    P Shankar
    Research Scholar's Program at the NIH, Howard Hughes Medical Institute, Bethesda, MD 20892, USA
    Vaccine 20:744-55. 2001
    ..The ability to augment immune responses using poxvirus-based vaccines containing multiple costimulatory molecule transgenes can now be addressed in the rhesus macaque model...
  21. ncbi request reprint Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity
    Wilhelmina M Aarts
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 62:5770-7. 2002
    ....
  22. ncbi request reprint Rational antigen modification as a strategy to upregulate or downregulate antigen recognition
    S I Abrams
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Curr Opin Immunol 12:85-91. 2000
    ....
  23. pmc Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:3060-9. 2008
    ..Carcinoembryonic antigen (CEA) and MUC-1 are overexpressed in a substantial proportion of common solid carcinomas. The primary end point of this study was vaccine safety, with immunologic and clinical responses as secondary end points...
  24. pmc Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations
    Amanda L Boehm
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:397-408. 2010
    ..We hypothesize here that two vaccine platforms targeting the same antigen might induce shared and distinct antigen-specific T-cell populations, and examined the possibility that two distinct vaccines could be used concomitantly...
  25. ncbi request reprint Acquisition of CD80 (B7-1) by T cells
    H Sabzevari
    Laboratory of Tumor Immunology and Biology, Division of Basic Sciences, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 166:2505-13. 2001
    ..Thus we demonstrate both immunostimulatory and immunoregulatory functions as a result of CD80 acquisition by different T cell populations...
  26. ncbi request reprint Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity
    Chie Kudo-Saito
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Cancer Immunol Immunother 56:1897-910. 2007
    ..These studies demonstrate for the first time that the level and avidity of antigen specific CTL, as well as the therapeutic outcome can be improved with the use of i.t. rF-IL-2 with vaccine regimens...
  27. pmc Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells
    Sixun Yang
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:5603-15. 2005
    ..To our knowledge, these studies are the first to show a methodology to induce higher-avidity human CTLs and have implications for the development of more efficient vaccines for a range of human cancers...
  28. pmc Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells
    Mary T Litzinger
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Leuk Res 34:1351-7. 2010
    ..This study supports the rationale for the use of CLL cells modified ex vivo with pre-specified recombinant MVA vectors as a whole tumor-cell vaccine for immunotherapy in CLL patients...
  29. ncbi request reprint Vaccine therapy of established tumors in the absence of autoimmunity
    James W Hodge
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1750, USA
    Clin Cancer Res 9:1837-49. 2003
    ..To our knowledge, the study reported here is the first description of a vaccine to a defined antigen where the regimen is potent enough to induce tumor therapy in the absence of autoimmunity...
  30. ncbi request reprint Selective induction of high avidity CTL by altering the balance of signals from APC
    SangKon Oh
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 170:2523-30. 2003
    ..Our data also suggested that dendritic cells play an important role in induction of high avidity CD8(+) CTL in vivo. This strategy to selectively induce higher avidity CTL may lead to more effective vaccines for viruses and cancer...
  31. ncbi request reprint Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49
    S V Kashmiri
    National Institutes of Health, National Cancer Institute, Laboratory of Tumor Immunology and Biology, Building 10, Room 5B38, Bethesda, MD 20892, USA
    Crit Rev Oncol Hematol 38:3-16. 2001
    ....
  32. ncbi request reprint Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules
    Kwong Y Tsang
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 11:1597-607. 2005
    ..Two antigens expressed noncoordinately on most human carcinomas are carcinoembryonic antigen (CEA) and MUC-1. We report here the construction and characterization of two viral vector vaccines to address these issues...
  33. pmc Multiple costimulatory modalities enhance CTL avidity
    James W Hodge
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:5994-6004. 2005
    ..The results reported in this study thus demonstrate multiple strategies that can be used in both antitumor and antiviral vaccine settings to generate higher avidity host T cell responses...
  34. pmc New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy
    Vittore Cereda
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:63-71. 2010
    ..These studies thus identify NGEP as a potential target for T cell-mediated immunotherapy of prostate cancer...
  35. ncbi request reprint Clinical safety of a viral vector based prostate cancer vaccine strategy
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 178:1515-20. 2007
    ....
  36. pmc Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant
    Robert J Lechleider
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 14:5284-91. 2008
    ..We hypothesized that a "metronomic" dose of interleukin 2 (IL-2) as a biological adjuvant would cause less toxicity while maintaining immunologic response...
  37. pmc Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:663-74. 2010
    ..This hypothesis-generating study provides evidence that patients with more indolent mCRPC (Halabi predicted survival > or =18 months) may best benefit from vaccine therapy...
  38. ncbi request reprint TRICOM vector based cancer vaccines
    Charlie T Garnett
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute NIH, Bldg 10, Rm 8B09, 10 Center Drive, Bethesda, MD 20892, USA
    Curr Pharm Des 12:351-61. 2006
    ..In this article, preclinical findings and recent clinical applications of TRICOM-based vaccines as a cancer immunotherapy are reviewed...
  39. ncbi request reprint A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine production
    Douglas W Grosenbach
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room 8B09, Bethesda, MD 20892 1750, USA
    Cell Immunol 222:45-57. 2003
    ....
  40. ncbi request reprint Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells
    Claudia Palena
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 104:192-9. 2004
    ..Ex vivo-generated antigen-specific T cells activated in this manner might be applied to experimental protocols or used for adoptive transfer in immunotherapy protocols...
  41. ncbi request reprint Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses
    James W Hodge
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute NIH, Building 10, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Res 63:7942-9. 2003
    ....
  42. ncbi request reprint Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity
    John W Greiner
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 62:6944-51. 2002
    ..The CEA.Tg/MIN mice present a clinically relevant model in which different CEA-based vaccine strategies can be tested on the spontaneous onset of intestinal tumorigenesis...
  43. ncbi request reprint Clinical trial designs for the early clinical development of therapeutic cancer vaccines
    R M Simon
    Branch of Biometric Research, Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7434, USA
    J Clin Oncol 19:1848-54. 2001
    ..Several conclusions for expediting the clinical development of effective cancer vaccines are proposed...
  44. ncbi request reprint Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2
    Chie Kudo-Saito
    Laboratories of Tumor Immunology and Biology and Experimental Immunology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 13:1936-46. 2007
    ....
  45. pmc 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines
    Chie Kudo-Saito
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 24:4975-86. 2006
    ..1, ICAM-1, and LFA-3)...
  46. ncbi request reprint Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells
    Michael B Bernstein
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 26:509-21. 2008
    ..Thus, these studies taken together form a scientific rationale for the use of recombinant yeast in vaccination protocols for cancer or infectious diseases...
  47. pmc A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 1750, USA
    Clin Cancer Res 12:1260-9. 2006
    ..Secondary end points were whether vaccine could be given safely with docetaxel and the clinical outcome of the treatment regimen...
  48. ncbi request reprint Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy
    Dale C Slavin-Chiorini
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer Gene Ther 11:665-80. 2004
    ..These studies thus support the concept of intratumoral vaccination employing vectors expressing costimulatory molecules...
  49. pmc Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells
    Sixun Yang
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 58:503-15. 2009
    ..Results indicated that enhanced costimulation greatly expanded human CEA-specific CD8(+) T cells and enhanced T-cell function, without inducing increased apoptosis of CEA-specific memory CD8(+) T cells...
  50. ncbi request reprint Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice
    Hasan E Zeytin
    Laboratories of Tumor Immunology and Biology, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 64:3668-78. 2004
    ....
  51. pmc Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen
    James W Hodge
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 27:4475-82. 2009
    ..The studies reported here show for the first time that priming with rMVA followed 7 days later by an rF boost at the same injection site, versus a distal site, generates superior tumor-specific immunity and antitumor activity...
  52. ncbi request reprint IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines
    E Reali
    San Raffaele Scientific Institute, Milan, Italy
    Cancer Res 61:5517-22. 2001
    ..This suggests a potential role for IgEs in the design of new cell-based tumor vaccines...
  53. ncbi request reprint The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses
    Mala Chakraborty
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive Room 8B09, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 56:1471-84. 2007
    ..These studies also underscore the importance of "drug" scheduling in vaccine combination therapies...
  54. pmc The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines
    Kenneth W Hance
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:2387-96. 2009
    ....
  55. pmc Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement
    Charlie T Garnett
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 14:3536-44. 2008
    ....
  56. ncbi request reprint Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Crit Rev Immunol 27:451-62. 2007
    ..In addition, clinical studies combining vaccines with radiation therapy, chemotherapy, and second-line hormone therapy have provided preliminary evidence of prolongation of time to disease progression and antigen cascade postvaccination...
  57. pmc Energy restriction and exercise differentially enhance components of systemic and mucosal immunity in mice
    Connie J Rogers
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Nutr 138:115-22. 2008
    ..05). These data suggest that ER and EX enhance some, but not all, components of the immune system and are likely working via different biological mechanisms to regulate NK and T-cell function...
  58. ncbi request reprint Cancer vaccines: preclinical studies and novel strategies
    Claudia Palena
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Adv Cancer Res 95:115-45. 2006
    ..The results from these studies would certainly support the development of new vaccination strategies toward cancer vaccines with enhanced clinical efficacy...
  59. ncbi request reprint Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity
    James W Hodge
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Detect Prev 26:275-91. 2002
    ....
  60. ncbi request reprint Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Medical Oncology Clinical Research Unit, Radiation Oncology Branch, and Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:3353-62. 2005
    ..One potential solution is the utilization of a well-tolerated systemic therapy (e.g., vaccine) in concert with local therapy...
  61. ncbi request reprint Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules
    Chie Kudo-Saito
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute NIH, 10 Center Drive, Room 8B09, Bethesda, MD 20892, USA
    Clin Cancer Res 10:1090-9. 2004
    ..c. priming and a replication defective avipox (fowlpox) virus containing the same four transgenes (designated rF-CEA/TRICOM) for i.t. vaccination or s.c. booster vaccinations...
  62. ncbi request reprint Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer
    Philip M Arlen
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Expert Rev Vaccines 2:483-93. 2003
    ..Newer approaches incorporating costimulatory molecules that enhance Tcell activation are also being investigated...
  63. ncbi request reprint Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses
    Chie Kudo-Saito
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute NIH, Building 10, Bethesda, MD 93042, USA
    Clin Cancer Res 11:2416-26. 2005
    ..c. route in inducing T-cell responses specific for CEA. These studies also showed that CEA was needed to be present both in the vaccine and in the tumor for therapeutic effects...
  64. ncbi request reprint Costimulatory molecules as adjuvants for immunotherapy
    James W Hodge
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Front Biosci 11:788-803. 2006
    ..This review will focus on the current state of the use of costimulatory molecules as adjuvants for immunotherapy, and in particular, as immunomodulators for cancer vaccines...
  65. pmc Vaccines with enhanced costimulation maintain high avidity memory CTL
    Sixun Yang
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 175:3715-23. 2005
    ..These studies thus have implications in the design of more effective vaccine strategies...
  66. ncbi request reprint Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer
    James Gulley
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Prostate 53:109-17. 2002
    ..A Phase I trial of recombinant vaccinia prostate specific antigen (rV-PSA) in patients with advanced metastatic prostate cancer was conducted. This report describes 42 patients who were treated with up to three monthly vaccinations...
  67. ncbi request reprint Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide
    E Salazar
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Int J Cancer 85:829-38. 2000
    ....
  68. pmc The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells
    Romaine I Fernando
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 120:533-44. 2010
    ..The selective expression of Brachyury in tumor cells and its role in EMT and cancer progression suggest that Brachyury may be an attractive target for antitumor therapies...
  69. pmc Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses
    Elizabeth K Wansley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:4316-25. 2008
    ..cerevisiae construct expressing human CEA (yeast-CEA) elicits CEA-specific T-cell responses and antitumor activity...
  70. pmc Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients
    Mary T Litzinger
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 58:955-65. 2009
    ..Given the immunodeficiencies characteristic of CLL, enhancing the antigen-presenting function of CLL cells and T cells simultaneously could be a distinct advantage in the effort to elicit antitumor immune responses...
  71. pmc Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine
    Benedetto Farsaci
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 127:1603-13. 2010
    ..It is also the first to demonstrate the efficacy of this sequence in reducing tumors in mouse models, providing a rationale for the design of combinational clinical studies...
  72. pmc Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy
    Ravi A Madan
    Laboratory of Tumor Immunology and Biology, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:4526-31. 2008
    ..We now report survival analyses at 6.5 years from the initiation of therapy with a median potential follow-up of 4.4 years...
  73. pmc Vaccines as monotherapy and in combination therapy for prostate cancer
    Julia Rotow
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Clin Transl Sci 3:116-22. 2010
    ....
  74. ncbi request reprint The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors
    Chie Kudo-Saito
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:4533-44. 2005
    ..The elimination of well-established tumors often proves elusive. Here we show that a multimodal immune-based therapy can be successfully employed to eliminate established tumors...
  75. ncbi request reprint A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy
    John C Morris
    Metabolism Branch, Laboratory of Pathology, Department of Laboratory Medicine, National Eye Institute, Bethesda, MD 20892 1457, USA
    Clin Cancer Res 13:958-64. 2007
    ..The primary end point was to determine drug toxicity. Tumor response, tumor-specific CD8+ T-cell immune responses, and modulation of CD4+ CD25+ FoxP3+ regulatory T-cell (Treg) numbers were secondary end points...
  76. ncbi request reprint Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 174:539-46. 2005
    ..This trial was designed to analyze toxicity, immunogenicity and time to treatment failure using vaccine, antiandrogen therapy or their sequential use...
  77. ncbi request reprint Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer
    Marc R Theoret
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Genitourin Cancer 5:347-50. 2007
  78. ncbi request reprint Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen
    S Zaremba
    Laboratory of Tumor Immunology and Biology, Division of Basic Sciences, National Cancer Institute, Bethesda, Maryland 20892 1750, USA
    Cancer Res 57:4570-7. 1997
    ..Most importantly, these CTLs were capable of lysing human tumor cells endogenously expressing CEA. The use of enhancer agonist CTL peptides may thus represent a new efficient direction for immunotherapy protocols...
  79. ncbi request reprint Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses
    K Uzendoski
    Howard Hughes Medical Institute Research Scholars Program at the NIH, Bethesda, MD 20892 1750, USA
    Hum Gene Ther 8:851-60. 1997
    ..These studies demonstrated the utility of a recombinant vaccinia virus to deliver and efficiently express ICAM-1 molecules on tumor cells for potential gene therapy and recombinant approaches to cancer immunotherapy...
  80. ncbi request reprint Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms
    E Reali
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 23:2909-21. 2005
    ..The study underscores the importance of defining the appropriate delivery form of an immune adjuvant, such as GM-CSF, relative to the immunization strategy to maximize the host immune responses against a specific antigen...
  81. pmc Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination
    David A Zaharoff
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, United States
    Vaccine 25:2085-94. 2007
    ..These mechanistic studies, taken together with the enhancement of a vaccine response, demonstrate that chitosan is a promising and safe platform for parenteral vaccine delivery...
  82. ncbi request reprint Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen
    Hiroshi Terasawa
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 8:41-53. 2002
    ..1/K(b) transgenic mice. These studies thus demonstrate the potential use of the PSA-3A agonist epitope in both peptide- and vector-mediated immunotherapy protocols for prostate cancer...
  83. ncbi request reprint A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1
    Kwong Yok Tsang
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:2139-49. 2004
    ....
  84. ncbi request reprint Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction
    Zohreh Tatari-Calderone
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 169:6162-9. 2002
    ..Moreover, we demonstrate that T cells that have acquired CD80 have the ability to stimulate other T cells. These data thus suggest that CD80 acquisition by human T cells might play a role in the immunoregulation of T cell responses...
  85. ncbi request reprint Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens
    Claudia Palena
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cytokine 24:128-42. 2003
    ..ELISPOT and ELISA assays for lymphotactin confirmed and extended these findings. These studies suggest a potential role for lymphotactin in the T-cell activation processes and subsequent anti-tumor events...
  86. pmc IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity
    Mary T Litzinger
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 110:3192-201. 2007
    ....
  87. ncbi request reprint External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing
    Mala Chakraborty
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Res 64:4328-37. 2004
    ..Thus, these studies demonstrate a new paradigm for the use of local tumor irradiation in combination with active specific vaccine therapy to elicit durable antitumor responses of established tumors...
  88. pmc Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules
    Claudia Palena
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 106:3515-23. 2005
    ..Therefore, our findings suggest that the use of CLL cells infected ex vivo with MVA-TRICOM or direct injection of MVA-TRICOM in patients with CLL has potential for the immunotherapy of CLL...
  89. pmc Impact of tumour volume on the potential efficacy of therapeutic vaccines
    J L Gulley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U S A
    Curr Oncol 18:e150-7. 2011
    ....
  90. pmc The use of monoclonal antibody B72.3 in the management of gynecologic malignancies
    J Simpson
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD 20892
    Yale J Biol Med 61:351-66. 1988
    ..These studies indicate the potential utility of MAb B72.3 in the diagnosis of gynecologic carcinoma...
  91. ncbi request reprint Molecular cloning and characterization of the complementary DNA of an M(r) 110,000 antigen expressed by human gastric carcinoma cells and upregulated by gamma-interferon
    S Shimada
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
    Cancer Res 54:3831-6. 1994
    ..Thus, the M(r) 110,000 molecule represents a potentially novel cell membrane glycoprotein whose possible role in human cancer and/or as a gamma-interferon-inducible gene product warrants further investigation...
  92. ncbi request reprint In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates
    D E Milenic
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, The National Institutes of Health, 9000 Rockville Pike, Bld. 10 Room B3B69, Bethesda, MD 20892, USA
    Cancer Biother Radiopharm 16:133-46. 2001
    ..The results described herein suggest that either of the cyclohexyl derivatives of DTPA may be suitable candidates for the labeling of immunoconjugates with alpha-emitting bismuth isotopes for radioimmunotherapeutic applications...
  93. ncbi request reprint Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4)
    Junko Yokokawa
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD
    Int J Cancer 121:595-605. 2007
    ..The studies reported here are the first to describe a PAGE4 CTL epitope and its agonist epitope, and thus identify PAGE4 as a potentially useful target for vaccine-mediated therapy of prostate cancer...
  94. pmc Chitosan solution enhances the immunoadjuvant properties of GM-CSF
    David A Zaharoff
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, United States
    Vaccine 25:8673-86. 2007
    ..We conclude that chitosan solution is a promising delivery platform for the sustained, local delivery of rGM-CSF...
  95. ncbi request reprint The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Int J Gastrointest Cancer 32:1-6. 2002
    ..Autologous dendritic cells (DCs) loaded with tumor antigens are particularly potent at inducing tumor antigen-specific immune responses...
  96. ncbi request reprint Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas
    John L Marshall
    Lombardi Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Clin Oncol 23:720-31. 2005
    ..We describe here the first trial in humans of the CEA-TRICOM vaccines (also including an enhancer agonist epitope within the CEA gene)...
  97. ncbi request reprint Physiological relevance of antigen presentasome (APS), an acquired MHC/costimulatory complex, in the sustained activation of CD4+ T cells in the absence of APCs
    Jun Zhou
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA
    Blood 105:3238-46. 2005
    ....
  98. ncbi request reprint Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules
    Michael A Morse
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:3017-24. 2005
    ..To determine the safety and immunologic and clinical efficacy of a dendritic cell vaccine modified to hyperexpress costimulatory molecules and tumor antigen...